Overview

A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)

Status:
Recruiting
Trial end date:
2025-06-20
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine safety, including dose limiting toxicities, and the recommended phase 2 dose (RP2D) of EPI-7386 in separate combinations with (a) abiraterone acetate plus prednisone or prednisolone (AAP) and (b) apalutamide (dose-finding) and to determine the antitumor activity of EPI-7386 in separate combinations with (a) AAP and (b) apalutamide (dose-expansion).
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Janssen Research & Development, LLC
Treatments:
Abiraterone Acetate
Prednisolone
Prednisone
Criteria
Inclusion Criteria:

- Histologically confirmed prostate adenocarcinoma

- Must be able to continue Gonadotropin-releasing hormone agonist (GnRHa) during the
study if not surgically castrate

- Eastern Cooperative Oncology Group (ECOG) performance status grade of 0, 1, or 2

- Must be able to swallow oral medicines

- Contraceptive use by men (and female partners of men enrolled in the study who are of
childbearing potential or are pregnant) (birth control) use should be consistent with
local regulations regarding the use of contraceptive methods for participants
participating in clinical studies

- Willing and able to adhere to the prohibitions and restrictions specified in this
protocol

Exclusion Criteria:

- Known central nervous system (CNS) metastases

- Non-metastatic castration-resistant prostate cancer (CRPC) (biochemical or
locoregional disease only) is excluded from trial participation

- Evidence of predominant neuroendocrine/small cell carcinoma features in archival or
baseline tumor biopsy specimen(s)

- Symptomatic or impending spinal cord compression, except if participant has received
definitive treatment and demonstrates evidence of clinically stable disease

- Known disorder affecting gastrointestinal absorption